Related Experiment Video

Updated: Jun 6, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Comment on "Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from

Jiahua Liu1, Guangzhen Wu1

  • 1Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.

Journal of the American Academy of Dermatology
|June 4, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Indolent systemic mastocytosisKIT D816V inhibitorPIONEERavapritinibcutaneous mastocytosisskin lesion

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...